Trials on Lungs and airways15

The following clinical trials are currently offered in Germany in this group.

15 matching trials

INFORM2 NivEntRecruiting

A single-arm study of the treatment of high-risk tumors with nivolumab and entinostat in children and adolescents

So-called high-risk tumors often progress very rapidly despite optimal treatment and are usually resistant to standard therapies. Immunotherapies and targeted drugs, such as the study drugs nivolumab and entinostat, offer new hope. Previous studies suggest that this combination may inhibit tumor growth in tumors with specific genetic characteristics. The goal of the INFORM2 study is to to investigate the efficacy of the combination therapy of nivolumab and entinostat in children and adolescents with treatment-resistant or recurrent high-risk tumors, and to compare whether the efficacy of this combination therapy differs in tumors with specific genetic alterations compared to those without these characteristics. Patients between the ages of 2 and 21 with a brain tumor or solid tumor classified as high-risk are eligible to participate. The tumor must either have a myc(n) amplification, a high mutation burden, or high PD-L1 expression—or none of these characteristics.

2–21 years · Relapsed / refractory · Phase I/II

IMA401-101Recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of a New Drug (Name: IMA401) in Patients with Recurrent or Uncontrolled Breast Cancer

Solid tumors are cancers that develop in organs such as the lungs, liver, or breast. When these tumors progress and no longer respond to standard therapies, novel drugs may be considered as additional treatment options. The goal of the IMA401-TCER study is to investigate the safety and tolerability of the new drug IMA401, which specifically targets certain cancer cells. Eligible participants include women and men aged 18 and older with advanced or metastatic solid tumors, including breast cancer, that no longer respond to standard therapies and exhibit a specific genetic profile (HLA-positive and MAGEA4/8).

18 years and older · Relapsed / refractory · Phase I

INCB-84344-102

Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Pediatric Leukemias, Lymphomas, or Solid Tumors

When malignant diseases of the blood system (leukemias, lymphomas) or tumors of other organs/tissues (solid tumors) in childhood do not respond to standard therapy (refractory) or recur (relapse), there are often significantly fewer established treatment regimens than in adults. Ponatinib, a tyrosine kinase inhibitor (TKI), is already approved for use in adults for certain forms of leukemia. The aim of this study is to investigate the safety and efficacy of ponatinib in children and adolescents with various types of cancer and to determine the optimal dose for treatment. Patients between the ages of 1 and 17 with previously treated, relapsed, or refractory leukemias, lymphomas, or solid tumors are eligible to participate.

1–17 years · Relapsed / refractory · Phase I/II

PYNNACLERecruiting

PYNNACLE Trial with Rezatapopt (PC14586): A New Treatment for Advanced Tumors with the TP53 Y220C Mutation

Rezatapopt is a novel, as-yet-unapproved drug that was developed specifically for the Y220C mutation in the TP53 gene. This gene controls cell growth; when a mutation occurs, the p53 protein loses its protective function, allowing cancer cells to multiply uncontrollably. Rezatapopt is intended to restore the function of the p53 protein. The PYNNACLE study is intended for patients with advanced solid tumors who have this specific genetic alteration (TP53 Y220C mutation). The goal of the study is to investigate the safety and efficacy of the investigational drug Rezatapopt. Eligible participants include women and men aged 18 and older, and, under certain conditions, adolescents between the ages of 12 and 17. The tumors must carry the TP53 Y220C mutation and must have already been treated with at least one prior cancer therapy.

12 years and older · Relapsed / refractory · Phase I/II

BX43361Recruiting

Screening Study to Determine Biomarker Status in Patients with Advanced Non-Small-Cell Lung Cancer

In cases of advanced non-small cell lung cancer (NSCLC), surgery alone is usually not sufficient for treatment. In addition to radiation therapy or chemotherapy, immunotherapy is often recommended. For the use of immunotherapy, tests for specific genetic information and surface characteristics of the cancer cells (biomarker tests) are important for tailoring treatment to the individual. However, these tests are not yet universally available for every marker in clinical practice. The goal of the BX43361 study is to screen patients for the presence of specific biomarkers and to assess their potential eligibility for further studies and therapies. Women and men aged 18 and older with stage II or higher NSCLC are eligible to participate in this study.

18 years and older · Phase II

SGN-PDL1VRecruiting

A Study on the Safety and Tolerability of SGN-PDL1V, a New Antibody-Chemotherapy Combination Drug, in Patients with Advanced Triple-Negative Breast Cancer

Treatment options for advanced and/or metastatic triple-negative breast cancer have been limited to date. A new drug that utilizes a well-established mechanism of action—the combination of immunotherapy and chemotherapy—could represent a new treatment option. The goal of this study is to evaluate the new drug SGN-PDL1V in terms of dose, tolerability, and efficacy in triple-negative breast cancer as well as other tumors. Women and men with triple-negative breast cancer at the locally advanced or metastatic stage whose cancer cells express the surface protein PD-L1 and who have experienced disease progression or relapse during previous treatments and, in the opinion of their treating physicians, no longer have any standard treatment options available.

18 years and older · Relapsed / refractory · Phase I

CKFA115A12101Active, not recruiting

A new drug (designated KFA115) for the treatment of advanced or metastatic triple-negative breast cancer

Treatment options for advanced and/or metastatic triple-negative breast cancer have been limited to date. KFA115 could be a new drug for this condition. The goal of this study is to investigate the efficacy and safety of the study drug KFA115 as monotherapy and in combination with pembrolizumab in triple-negative breast cancer and other tumors. Women and men aged 18 and older with advanced tumors of various tissues and organs, including triple-negative breast cancer, are eligible to participate in this study if they have already undergone prior treatments.

18 years and older · Relapsed / refractory · Phase I

SentiNose PilotRecruiting

SentiNose – Evaluation of Sentinel Lymph Node Biopsy as a Treatment Option for Nasal Tumors

Sinonasal squamous cell carcinoma (SNSCC) is a rare, malignant cancer of the nasal cavity or paranasal sinuses that spreads to the surrounding lymph nodes at an early stage. Because SNSCC is rare, there are currently no standardized recommendations, particularly regarding preventive treatment of the lymph nodes. The goal of the SentiNose pilot study is to specifically investigate the so-called sentinel lymph node biopsy as a treatment approach for this rare form of cancer. Patients aged 18 and older who have a resectable tumor in the nasal region and for whom a cure is the goal are eligible to participate.

18 years and older · First line

AAV-AH-OI 02Recruiting

Research on New Gene Therapies for Lung Cancer: This study is testing suitable AAV vectors in the laboratory that are designed to specifically target tumor cells in non-small-cell lung cancer (AH-OI-02 study).

Gene therapy is considered an innovative treatment approach designed to specifically modify tumor cells genetically; however, the gene delivery vehicles—known as vectors—used in this therapy have so far often been unable to reliably distinguish between healthy and diseased cells. The goal of the AAV-AH-OI-02 study is to investigate which AAV vectors are particularly effective at targeting tumor cells in non-small cell lung cancer (NSCLC) in order to make treatment more targeted and better tolerated in the future. Eligible participants are individuals aged 18 and older with a previously untreated, primary non-small cell lung carcinoma who are scheduled to undergo surgery to remove the tumor. The study does not affect the actual treatment; instead, the tumor tissue removed during surgery is used exclusively for laboratory testing.

18 years and older · First line

ANTELOPERecruiting

Comparison of pemetrexed-free immunochemotherapy (atezolizumab/carboplatin/nab-paclitaxel) with standard immunochemotherapy (pembrolizumab/platinum/pemetrexed) in people with metastatic lung cancer (TTF-1 negative)

The standard treatment for people with newly diagnosed metastatic lung adenocarcinoma is immunochemotherapy, which often includes the active ingredient pemetrexed. However, there is evidence that this drug is not very effective in patients with certain cancer characteristics. The goal of the ANTELOPE study is to investigate whether pemetrexed-free immunochemotherapy is more effective in these patients than the standard pemetrexed-containing therapy. Women and men aged 18 and older who have been newly diagnosed with lung cancer exhibiting specific characteristics (metastatic, TTF-1-negative, PD-L1 < 50%) and who have not yet received systemic treatment are eligible to participate in this study.

18 years and older · First line · Phase II